Bone Mineral Density After Transitioning From Denosumab to Alendronate.
David Kendler, Arkadi Chines, Patricia Clark...
https://pubmed.ncbi.nlm.nih.gov/31665314/Actively Recruiting
Led by National Taiwan University Hospital · Updated on 2026-08-25
52
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating intravenous ibandronate and zoledronic acid as sequential treatments after stopping denosumab in postmenopausal women with osteoporosis who have used denosumab for less than three years. This open-label, randomized trial aims to provide early evidence on whether ibandronate offers similar protection as zoledronic acid, which is the current standard, to help inform future studies of longer-term denosumab use. Participants will be randomly assigned to receive either ibandronate at 3 mg every 3 months for 12 months or a single dose of zoledronic acid 5 mg over one year, starting about six months after their last denosumab injection. Following treatment, they will be monitored for a total of two years to observe the effects of these therapies on bone health. During the study, participants will undergo bone mineral density scans and have blood tests to measure bone turnover markers at baseline and throughout the 24-month period. Researchers will also assess pain levels using a visual analog scale and track any osteoporotic fractures or adverse events. This thorough follow-up will help determine the effectiveness and safety of these treatments after denosumab discontinuation.
CONDITIONS
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
F
Fon-Yih Tsuang Clinical Associate Professor, Ph.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Taiwan University Hospital
Lead Sponsor
National Taiwan University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants receive either intravenous ibandronate every 3 months or a single dose of intravenous zoledronic acid over 1 year, starting about 6 months after their last denosumab dose.
Visits every 3 months during treatment
Duration - 24 months
Participants are monitored for bone health, fractures, pain, and any side effects for 2 years after completing the treatment.
Regular follow-up visits during monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
David Kendler, Arkadi Chines, Patricia Clark...
https://pubmed.ncbi.nlm.nih.gov/31665314/Athanasios D Anastasilakis, Socrates E Papapoulos, Stergios A Polyzos...
https://pubmed.ncbi.nlm.nih.gov/31433518/Paul D Miller, Michael A Bolognese, E Michael Lewiecki...
https://pubmed.ncbi.nlm.nih.gov/18539106/Henry G Bone, Rachel B Wagman, Maria L Brandi...
https://pubmed.ncbi.nlm.nih.gov/28546097/Sabashini K Ramchand, Joy N Tsai, Hang Lee...
https://pubmed.ncbi.nlm.nih.gov/37798320/Anne Sophie Sølling, Torben Harsløf, Bente Langdahl
https://pubmed.ncbi.nlm.nih.gov/33813753/I Fogelman, G M Blake
https://pubmed.ncbi.nlm.nih.gov/11138687/Dennis M Black, Douglas C Bauer, Eric Vittinghoff...
https://pubmed.ncbi.nlm.nih.gov/32707115/M S LeBoff, S L Greenspan, K L Insogna...
https://pubmed.ncbi.nlm.nih.gov/35478046/Henry G Bone, Michael A Bolognese, Chui Kin Yuen...
https://pubmed.ncbi.nlm.nih.gov/21289258/National Taiwan University Hospital
Lead Sponsor
National Taiwan University
Collaborating Sponsor